PLACENTAL INTEGRATIVE OMICS APPROACH RELATED TO BREAST CANCER DURING PREGNANCY

• Grant number: 24/19220-5
• Support Opportunities: Regular Research Grants
• Start date: February 01, 2025
• End date: January 31, 2027
• Field of knowledge: Biological Sciences - Physiology - Physiology of Organs and Systems
• Mobility Program: SPRINT - Projetos de pesquisa - Mobilidade
• Principal Investigator: Laís Rosa Viana
• Grantee: Laís Rosa Viana
• Principal researcher abroad: Olivier E Pardo
• Institution abroad: Imperial College London, England
• Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Associated researchers: Leisa Lopes Aguiar
• Associated research grant: 21/08931-0 - Cancer and pregnancy: proteomic, transcriptomic and metabolic alterations in placenta from pregnant women with cancer and Wistar pregnant Walker 256 tumour-bearing rats, AP.JP

Abstract

The SPRINT proposal will be a great opportunity to establish a collaborative partnership between Dr. Laís Rosa Viana from Unicamp - Principal Investigator of the Young Researcher (FAPESP process #2021/08931-0) and Regular Research (FAPESP process #2023/01310-5) Projects - and Dr. Olivier E. Pardo from Imperial College London - Principal Investigator of the multiple funded projects, including the BCRT/8121 project on FGF2 signalling in osteosarcoma and the WCR23-0026 project on RSK isoform-specific signalling. This partnership will involve the placental omics profiling (transcriptomics, miRomics, proteomics and metabolomics) of pregnant patients with breast cancer. The profiling will be performed by Dr. Viana's group and the subsequent omics data integration in collaboration with Dr. Pardo's group. The exchange activities related to this proposal will include: 1) those aiming to contribute to the communities of both Institutions, with a focus on postgraduate students and 2) exchange activities promoting the ongoing research in Brazil and the Partner Institution. These exchange activities will be carried out by the principal investigators and a post-doctoral researcher will be divided as part of 4 missions along 24 months. The results obtained during these exchanges will form the basis for future medium/long-term collaborative funding applications assessing the signalling crosstalk between trophoblasts and breast cancer cells to predict novel targeted therapies for pregnant breast cancer patients. (AU)